ENHERTU: Targeted therapy shaping HER2-positive cancer care

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 9:09 PM ET. Details in the imprint.

ENHERTU is one of Daiichi Sankyo's most visible oncology brands in the United States, positioned as a HER2-directed antibody-drug conjugate for select patients with metastatic breast, gastric and other HER2-expressing cancers. It is jointly developed and commercialized with AstraZeneca and has become a reference point for targeted therapy in HER2-positive disease. The drug is available in the U.S. as a prescription-only intravenous infusion given in specialized oncology settings, with dosing and scheduling determined by the treating oncologist based on the FDA-approved label.

What ENHERTU does and how it is used in the U.S.

According to publicly available U.S. prescribing information, ENHERTU (fam-trastuzumab deruxtecan-nxki) is indicated for adult patients with unresectable or metastatic HER2-positive breast cancer who have received prior anti-HER2-based regimens in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant therapy. Beyond breast cancer, ENHERTU also holds FDA approvals in HER2-positive gastric or gastroesophageal junction adenocarcinoma and in certain HER2-mutant or HER2-low solid tumors, giving it a broader reach across oncology than many single-tumor drugs. These indications are supported by clinical data showing tumor response in heavily pretreated patients, and the brand is now part of standard discussions in HER2-targeted treatment pathways among U.S. oncologists.

ENHERTU is administered as an intravenous infusion, typically every three weeks, in a hospital or infusion center equipped to manage cytotoxic chemotherapies and targeted biologics. Dosing is weight-based and follows specific protocols, with adjustments or treatment interruptions recommended in the event of adverse reactions such as interstitial lung disease, neutropenia or cardiotoxicity. Because ENHERTU combines a monoclonal antibody with a topoisomerase I inhibitor payload, it requires careful patient selection and monitoring, often including baseline and periodic imaging, cardiac assessment and pulmonary evaluation as outlined in the prescribing information. Patients receive ENHERTU only under supervision of an oncologist or a healthcare professional experienced in anticancer agents; it is not available as an oral medication or for self-administration.

In the U.S., ENHERTU is distributed through specialty pharmacies and institutional channels rather than typical retail drugstores, reflecting its status as a complex oncology infusion therapy. Hospitals and oncology practices usually obtain ENHERTU via group purchasing organizations or specialty distributors, and reimbursement involves both medical benefit coverage and prior authorization steps through commercial insurers and Medicare. For patients, this often means that out-of-pocket costs are shaped by their insurance design rather than list price alone, and Daiichi Sankyo and AstraZeneca operate assistance programs that may help eligible individuals address co-pays or access challenges. For shoppers considering treatment options with their oncologist, it makes sense to discuss both the clinical fit of ENHERTU and the expected financial coverage with the care team and insurer before starting therapy.

While list price figures can change and require up-to-date verification, ENHERTU is generally regarded as a high-cost biologic consistent with other modern oncology antibody-drug conjugates. Pricing is typically based on vial strength and dosage, and healthcare providers bill payers according to administered dose per cycle. Because oncology pricing and reimbursement systems are complex and vary by payer and state, patients are usually advised to review benefit estimates, co-insurance rates and any manufacturer support options before initiating therapy, rather than relying on general average cost figures. U.S. availability is broad at major cancer centers, academic hospitals and community oncology networks, and the product features in treatment discussions at large clinical meetings such as ASCO, where Daiichi Sankyo's ADC portfolio has been a recurring topic.

The mechanism of action of ENHERTU is characteristic of antibody-drug conjugates: the trastuzumab-based antibody targets HER2-expressing tumor cells, binds to the receptor, is internalized, and then releases a potent cytotoxic payload inside the cell. This targeted delivery aims to concentrate the chemotherapeutic effect in cancer cells while limiting systemic exposure, though clinically meaningful toxicities still occur and are managed through established safety protocols. ENHERTU carries warnings and precautions related to interstitial lung disease/pneumonitis, neutropenia, left ventricular dysfunction and embryo-fetal toxicity, and prescribers are instructed to monitor for respiratory symptoms, blood counts and cardiac function, and to provide supportive care and dose modifications when indicated. Such safety guidance makes adherence to the official prescribing information crucial for safe use in practice.

From a portfolio perspective, ENHERTU sits at the core of Daiichi Sankyo's antibody-drug conjugate strategy, which also includes other late-stage ADCs that are part of the company's collaboration with Merck and AstraZeneca. Public communications from Merck in 2026 referenced manufacturing and supply planning for the ADC portfolio, highlighting how these complex biologic therapies require forward-looking capacity investments and coordination between partners. For Daiichi Sankyo, ENHERTU's growth in established indications and potential label expansions can contribute significantly to oncology revenue and to the perception of the company as a key ADC innovator among physicians and industry observers. Shares of Daiichi Sankyo (JP3475350009, ticker DSNKY) last traded in the U.S. over-the-counter market; investors can find current price data via their brokerage platforms using the ADR ticker symbol and ISIN.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.